To reliably demonstrate the effect of XRCC1 variants (Arg399Gln, Arg280His, and Arg194Trp) on childhood ALL risk, we conduct a meta-analysis of all eligible studies to resolve this pivotal issue. Here, XRCC1 is linked to acute lymphoblastic leukemia.